Dyne Therapeutics, Inc. (NASDAQ:DYN – Get Free Report)’s stock price crossed below its 50-day moving average during trading on Monday following insider selling activity. The stock has a 50-day moving average of $16.81 and traded as low as $16.49. Dyne Therapeutics shares last traded at $16.70, with a volume of 1,849,642 shares trading hands.
Specifically, CFO Erick Lucera sold 1,991 shares of the business’s stock in a transaction that occurred on Friday, November 13th. The stock was sold at an average price of $16.82, for a total transaction of $33,488.62. Following the completion of the transaction, the chief financial officer owned 117,775 shares in the company, valued at $1,980,975.50. The trade was a 1.66% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Analysts Set New Price Targets
DYN has been the topic of several research analyst reports. Raymond James Financial reaffirmed a “strong-buy” rating and issued a $37.00 price objective on shares of Dyne Therapeutics in a research report on Tuesday, September 8th. Stifel Nicolaus set a $37.00 target price on Dyne Therapeutics in a research report on Wednesday, September 30th. JPMorgan Chase & Co. lowered shares of Dyne Therapeutics from a “neutral” rating to an “underweight” rating and lowered their target price for the company from $17.00 to $10.00 in a research note on Wednesday, September 9th. Jefferies Financial Group reissued a “buy” rating and set a $50.00 target price on shares of Dyne Therapeutics in a research note on Wednesday, September 30th. Finally, HC Wainwright cut their price target on shares of Dyne Therapeutics from $50.00 to $32.00 and set a “buy” rating on the stock in a report on Wednesday, September 30th. One research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, two have assigned a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $31.29.
Dyne Therapeutics Stock Down 2.7%
The company has a quick ratio of 12.99, a current ratio of 12.99 and a debt-to-equity ratio of 0.21. The stock has a market cap of $3.13 billion, a P/E ratio of -4.60 and a beta of 1.22. The company’s 50 day moving average price is $16.81 and its two-hundred day moving average price is $19.32.
Dyne Therapeutics (NASDAQ:DYN – Get Free Report) last announced its quarterly earnings data on Thursday, November 5th. The company reported ($1.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.91) by ($0.15). During the same period in the prior year, the company earned ($0.76) earnings per share. As a group, research analysts expect that Dyne Therapeutics, Inc. will post -3.81 earnings per share for the current year.
Institutional Investors Weigh In On Dyne Therapeutics
Several hedge funds have recently made changes to their positions in the company. BlackRock Inc. bought a new position in shares of Dyne Therapeutics during the 2nd quarter worth $275,500,000. Jupiter Topco LLC purchased a new position in shares of Dyne Therapeutics during the second quarter valued at $266,634,000. Bank of America Corp DE bought a new stake in shares of Dyne Therapeutics in the second quarter valued at about $49,604,000. Palo Alto Investors LP bought a new stake in shares of Dyne Therapeutics in the second quarter valued at about $36,591,441. Finally, Perceptive Advisors LLC raised its holdings in shares of Dyne Therapeutics by 34.2% in the first quarter. Perceptive Advisors LLC now owns 4,668,839 shares of the company’s stock valued at $84,646,000 after acquiring an additional 1,189,895 shares in the last quarter. 96.68% of the stock is currently owned by hedge funds and other institutional investors.
Dyne Therapeutics Company Profile
Dyne Therapeutics is a clinical-stage biotechnology company developing therapies for genetically driven muscle diseases. Its research uses the FORCE platform, which is designed to deliver oligonucleotide medicines to muscle tissue. The company’s programs include DYNE-101 for myotonic dystrophy type 1 and DYNE-251 for Duchenne muscular dystrophy in patients whose genetic mutations are amenable to exon 51 skipping. Dyne has also pursued a program for facioscapulohumeral muscular dystrophy. Its therapies remain in development, and the company does not have an approved product.
See Also
- Five stocks we like better than Dyne Therapeutics
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Dyne Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dyne Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
